Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19016323 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL29323035 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL29323216 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL18085393 | 0.84 | LMNA (0.60) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL31072542 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL7372302 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL19016325 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL30823376 | 0.82 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL29323224 | 0.82 | LMNA (0.58) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL24923326 | 0.82 | HTT (0.62) | SMN1; SMN2LMNAL3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | SMN1; SMN2 4880/4885LMNA 3705/4885L3MBTL1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.